Oral Lefamulin vs Moxifloxacin for Early Clinical Response Among Adults With Community-Acquired Bacterial Pneumonia: The LEAP 2 Randomized Clinical Trial

IMPORTANCE: New antibacterials are needed to treat community-acquired bacterial pneumonia (CABP) because of growing antibacterial resistance and safety concerns with standard care. OBJECTIVE: To evaluate the efficacy and adverse events of a 5-day oral lefamulin regimen in patients with CABP. DESIGN,...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:JAMA
Main Authors: Alexander, Elizabeth, Goldberg, Lisa, Das, Anita F., Moran, Gregory J., Sandrock, Christian, Gasink, Leanne B., Spera, Patricia, Sweeney, Carolyn, Paukner, Susanne, Wicha, Wolfgang W., Gelone, Steven P., Schranz, Jennifer
Formato: Artigo
Idioma:Inglês
Publicado: American Medical Association 2019
Assuntos:
Original Investigation
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC6865224/
https://ncbi.nlm.nih.gov/pubmed/31560372
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1001/jama.2019.15468
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares